The Effect of Exogenous Surfactant on Moderate and Severe Stages of Covid-19 Induced Ards: The Pilot Study of a Clinical Trial Publisher



Fani K¹ ; Ghahremani M¹ ; Fathi M¹ ; Massoudi N¹ ; Tavana S² ; Nooraee N¹ ; Alamdari NM³ ; Besharat S⁴ ; Abrandabadi AN¹ ; Pirsalehi A² ; Khatiri MAK¹ ; Pouya MA⁵ ; Rajaei S⁶ ; Dabbagh A¹
Source: Iranian Journal of Pharmaceutical Research Published:2021

Abstract

COVID-19 pandemic has created a global health challenge. Many pharmaceuticals have been repurposed as potential treatments, though many have not been promising. Due to the inflammatory and destructive effects of the virus on alveolar cells, the effect of exogenous surfactant was assessed as a potential treatment of lung dysfunction in COVID-19 patients. In this pilot study of the clinical trial, 49 patients aged 35-80 years with COVID-19 admitted in ICU entered the study (22 patients intubated and 23 had face masks; 4 patients in the control arm). The treatment arm patients received two consecutive doses of surfactant. P/F ratio (based on serial blood gas analyses before and 12 hours after 2 doses of surfactant) and also, clinical outcomes were assessed.in COVID-19 adult patients, surfactant significantly improved pulmonary P/F ratio both in intubated and face mask COVID-19 patients (increasing from 119.2 ± 51.7 to 179.4 ± 115.5). The rate of extubation was much better than similar country-wide studies. Surfactant significantly alleviates the respiratory status in moderate to severe COVID-19 ARDS with two consecutive 100 mg doses of surfactant (with 6 hours’ interval) though previous studies have been controversial, regarding the effect of surfactant in general forms of ARDS. Higher doses might have better effects, mandating more trials. © 2021, Iranian Journal of Pharmaceutical Research. All rights reserved.